Axsome Therapeutics, Inc (AXSM) Financial Statements
Historical financial data — 38 statements covering FY2022–FY2025
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which ther...
Axsome Therapeutics, Inc's revenue increased 65.5% year over year, from $385.7M to $638.5M.
Net income increased 36.2% over the same period, from $-287.2M to $-183.2M.
Total debt decreased by 34.8% to $117.7M.
The debt-to-equity ratio stands at 1.33, indicating a elevated leverage profile.
Operating cash flow grew 27.3% to $-93.4M.
Axsome Therapeutics, Inc maintains a negative net profit margin of -28.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $141.3M+49.4% | $-78.4M | $-71.4M | $-71.4M | $-61.2M | $611.6M | $176.8M | $278.8M |
| Q3 FY2023 | $199.1M+40.9% | $-140.6M | $-133.6M | $-133.6M | $-114.7M | $600.9M | $177.4M | $269.5M |
| Q2 FY2024 | $162.2M-18.5% | $-147.7M | $-145.3M | $-145.3M | $-83.6M | $548.2M | $179.3M | $102.9M |
| Q3 FY2024 | $266.9M+64.6% | $-212.3M | $-207.9M | $-207.9M | $-102.2M | $561.5M | $180.0M | $92.9M |
| Q1 FY2025 | $121.5M-54.5% | $-59.4M | $-57.0M | $-57.0M | $-43.4M | $596.7M | $181.4M | $53.2M |
| Q2 FY2025 | $271.5M+123.5% | $-107.4M | $-93.7M | $-93.7M | $-75.8M | $639.8M | $117.5M | $73.1M |
| Q3 FY2025 | $442.5M+63.0% | $-154.6M | $-139.8M | $-139.8M | $-74.8M | $669.3M | $117.6M | $73.7M |
| Q1 FY2026 | $191.2M-56.8% | $-64.5M | $-63.4M | $-63.4M | $-20.7M | $713.6M | $117.8M | $54.6M |
Balance Sheet Summary (Latest Period)
Axsome Therapeutics, Inc (AXSM) Financial Statements & Revenue History
Axsome Therapeutics, Inc (AXSM) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $205.49 with a market capitalization of $11. This page provides 38 historical financial statements for Axsome Therapeutics, Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Axsome Therapeutics, Inc reported revenue of $638 million, representing 65.5% year-over-year growth. The net profit margin of -28.7% indicates the company is currently unprofitable. The debt-to-equity ratio of 1.33 indicates elevated leverage.
AXSM Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Axsome Therapeutics, Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether AXSM is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track AXSM's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Axsome Therapeutics, Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of AXSM's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use AXSM Financial Data
Investors use Axsome Therapeutics, Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare AXSM's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how AXSM's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View AXSM's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Axsome Therapeutics, Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.AXSM trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.